These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 30118932

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I, von Podewils F, Möddel G, Bauer S, Klein KM, Paule E, Reif PS, Willems LM, Zöllner JP, Kunz R, Runge U, Kurlemann G, Schubert-Bast S, Rosenow F, Strzelczyk A.
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. BRIVEST: A 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam.
    Naddell S, Manuel M, Cavill R, White P, Sieradzan K.
    Epilepsy Behav; 2023 Jan; 138():108985. PubMed ID: 36442261
    [Abstract] [Full Text] [Related]

  • 7. Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation.
    Adewusi J, Burness C, Ellawela S, Emsley H, Hughes R, Lawthom C, Maguire M, McLean B, Mohanraj R, Oto M, Singhal S, Reuber M.
    Epilepsy Behav; 2020 May; 106():106967. PubMed ID: 32179501
    [Abstract] [Full Text] [Related]

  • 8. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up.
    Strzelczyk A, Zaveta C, von Podewils F, Möddel G, Langenbruch L, Kovac S, Mann C, Willems LM, Schulz J, Fiedler B, Kurlemann G, Schubert-Bast S, Rosenow F, Beuchat I.
    Epilepsia; 2021 Dec; 62(12):2994-3004. PubMed ID: 34608628
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
    Gillis RME, Wammes-van der Heijden EA, Schelhaas HJ, Tan IY, Festen DAM, Majoie MHJM.
    Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
    Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D'Souza J.
    Epilepsy Behav; 2015 Nov; 52(Pt A):165-8. PubMed ID: 26432008
    [Abstract] [Full Text] [Related]

  • 12. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
    Green SF, Hare N, Kassam M, Rugg-Gunn F, Koepp MJ, Sander JW, Rajakulendran S.
    Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166
    [Abstract] [Full Text] [Related]

  • 13. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S.
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [Abstract] [Full Text] [Related]

  • 14. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.
    Fonseca E, Guzmán L, Quintana M, Abraira L, Santamarina E, Salas-Puig X, Toledo M.
    Epilepsy Behav; 2020 Jan; 102():106657. PubMed ID: 31731108
    [Abstract] [Full Text] [Related]

  • 15. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
    Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F, De Maria G, Didato G, Falcicchio G, Fanella M, Ferlazzo E, Fisco G, Gangitano M, Giallonardo AT, Giorgi FS, La Neve A, Mecarelli O, Montalenti E, Piazza F, Pulitano P, Quarato PP, Ranzato F, Rosati E, Tassi L, Di Bonaventura C, BRIVAFIRST Group Membership.
    CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
    Asadi-Pooya AA, Sperling MR, Chung S, Klein P, Diaz A, Elmoufti S, Schiemann J, Whitesides J.
    Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S.
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.